Astrazeneca Pharma India Ltd. (ASTRAZEN) 52 Week Low Streak: Second Straight Session Near Yearly Low

Astrazeneca Pharma India Ltd. 52 Week Low Streak has now extended to its second straight session, with the stock still trading within 2% of its 52-week low. Across the streak, the share has slipped 0.19%, and the latest trough remains the key reference point for readers tracking the Astrazeneca Pharma India Ltd. 52 Week Low Streak. The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.

The stock closed at Rs 6275.45 versus the previous close of Rs 6254.35, after opening at Rs 6225.65 and touching an intraday high of Rs 6280 and a low of Rs 6225.65. The market capitalisation stands at Rs 15,635.88 crore. For readers, the point is not just the one-session change; it is the persistence of the Astrazeneca Pharma India Ltd. 52 Week Low Streak across consecutive trading days, which keeps the yearly low in focus as a live market signal.

Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 6,275.45
Previous Close	Rs 6,254.35
Today's Move	+Rs 21.1 (+0.34%)
Open	Rs 6,225.65
High	Rs 6,280
Low	Rs 6,225.65
Market Capitalisation	Rs 15,635.88 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,275.45 versus the previous close of Rs 6,254.35, a rise of 0.34%. The stock opened at Rs 6,225.65, reached a high of Rs 6,280, touched a low of Rs 6,225.65.

Astrazeneca Pharma India Ltd. 52 Week Low Streak began with a narrow session around the lower end of the day’s range, and today’s move kept that pattern intact. The share price finished at Rs 6275.45, up Rs 21.10 or 0.34% from the previous close of Rs 6254.35. The day’s open at Rs 6225.65 was below the close, while the high of Rs 6280 capped the session only slightly above the closing level. The low for the day was also Rs 6225.65, which means the stock spent the entire session near the bottom of its range.

That detail matters because the Astrazeneca Pharma India Ltd. 52 Week Low Streak is not being driven by a single sharp shock alone; it is persisting across sessions. The current level remains very close to the one-year trough, and the move across the streak remains modest at -0.19%. In the context of Astrazeneca Pharma India Ltd. Share Price reporting, this is a decline story rather than a recovery story, with the yearly low acting as the main reference zone. The market capitalisation of Rs 15,635.88 crore places the stock firmly among the more closely watched names in the healthcare pack.

What The Repeated 52-Week Lows Show

Astrazeneca Pharma India Ltd. 52 Week Low Streak is important because it shows persistence, not just an isolated weak day. The stock has traded within 2% of its 52-week low for a second straight session, which keeps the one-year trough in the frame for traders, analysts and long-term readers following Astrazeneca Pharma India Ltd. Stock News. The supplied data confirms the pattern of repeated lows, but it does not identify a company-specific catalyst behind the move.

In practical terms, back-to-back proximity to a yearly low often tells the market that the stock is not yet finding a stable base. That does not mean a fresh breakdown has been confirmed today, and it does not mean a reversal is due either. It simply means the Astrazeneca Pharma India Ltd. 52 Week Low Streak remains active and that the stock continues to sit in the zone that investors commonly associate with 52 Week Low Stocks and Stocks At One Year Low Today. The fact that the current low remains the key reference point is the main story, not the daily gain or loss.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 15,635.88 crore
P/E Ratio	92.18x
P/B Ratio	17.29x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.58%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 92.18x, P/B 17.29x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15635.88 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 92.18x, P/B at 17.29x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.58%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 28.2x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	92.18x
Benchmark Median P/E	28.2x
Benchmark Average P/E	41.75x
Benchmark P/E Range	0x to 699.02x
Company P/B Ratio	17.29x
Benchmark Median P/B	2.87x
Company ROE	23.02%
Benchmark Median ROE	11.7%
Company ROCE	31.24%
Benchmark Median ROCE	13.46%
Company Market Capitalisation	Rs 15,635.88 crore
Benchmark Median Market Cap	Rs 773.14 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 92.18x, which is above the benchmark median of 28.2x, a difference of +226.88%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Marksans Pharma Ltd.	MARKSANS	15,026.91	30.06	4.89	15.31	21.1
Natco Pharma Ltd.	NATCOPHARM	14,832.09	13.21	1.62	16.3	17.16
Glenmark Life Sciences Ltd.	ALIVUS	16,695.69	27.69	4.79	18.41	24.61
Concord Biotech Ltd.	CONCORDBIO	14,585.07	53.56	7.11	13.54	18.04
Alembic Pharmaceuticals Ltd.	APLLTD	16,790.42	24.38	2.89	12.35	11.74

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 92.18x compared with the displayed peer median of 27.69x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,635.88 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching

• Astrazeneca Pharma India Ltd. 52 Week Low Streak has continued for a second straight session, keeping the yearly low in focus.
• The stock’s Astrazeneca Pharma India Ltd. Share Price remains close to its 52-week trough, so readers are tracking whether the low zone stabilises.
• The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause.
• Valuation remains rich versus the industry median, even though return ratios are comparatively strong.
• Healthcare sector and pharmaceutical peer comparison help frame whether the current Astrazeneca Pharma India Ltd. Stock Performance is isolated or part of a wider re-rating.

About The Company

Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company’s current market capitalisation is Rs 15,635.88 crore, and the latest market read keeps the Astrazeneca Pharma India Ltd. 52 Week Low Streak under close watch. As a listed pharmaceutical company, it is followed for its financial quality, earnings profile and comparative valuation within the domestic healthcare space.

For investors and market readers, the relevant context is not only the daily price movement but how the stock behaves relative to its one-year low, its sector peers and its stated fundamentals. That is why Astrazeneca Pharma India Ltd. Share Price, valuation ratios and profitability metrics all matter together when assessing the current phase of weakness.

Frequently Asked Questions

Why is Astrazeneca Pharma India Ltd. still near its 52-week low?

Ans. The supplied data shows that Astrazeneca Pharma India Ltd. has traded within 2% of its 52-week low for a second straight session. It confirms the pattern, but it does not identify a company-specific reason for the continued weakness.

What does the Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?

Ans. It means the stock has remained close to its yearly low for consecutive sessions. For this Astrazeneca Pharma India Ltd. 52 Week Low Streak, the move across the streak is -0.19%, which keeps the breakdown in focus.

Is Astrazeneca Pharma India Ltd. under pressure compared with peers?

Ans. The stock trades at a much higher P/E and P/B than the industry median and several named peers. That makes the Astrazeneca Pharma India Ltd. Share Price look expensive relative to many comparables in the same industry.

How strong are the profitability ratios?

Ans. ROE is 23.02% and ROCE is 31.24%, both above the supplied industry medians. The Astrazeneca Pharma India Ltd. Stock Analysis therefore shows stronger return ratios even though the price remains near the yearly low.

What is the current market capitalisation of Astrazeneca Pharma India Ltd.?

Ans. The company’s market capitalisation is Rs 15,635.88 crore. That size matters when reading the Astrazeneca Pharma India Ltd. Stock News because it places the name among closely tracked pharmaceutical companies in the healthcare space.

Does the data confirm a reversal from the low?

Ans. No. The stock closed slightly higher on the day, but the Astrazeneca Pharma India Ltd. 52 Week Low Streak is still intact. The supplied numbers do not support a conclusion that the broader weakness has ended.

How should readers interpret the repeated low pattern?

Ans. They should treat it as a price-pattern signal, not a cause-based explanation. The repeated proximity to the yearly low suggests the stock remains in a weak zone, while the underlying reason remains unconfirmed in the supplied data.

Where does Astrazeneca Pharma India Ltd. stand in the healthcare sector?

Ans. Within the Healthcare sector and Pharmaceuticals & Drugs industry, the company stands out for its premium valuation and solid profitability ratios. The Astrazeneca Pharma India Ltd. 52 Week Low Streak shows the price is not matching those fundamentals in the.

Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.